Amazon Web Services launched Amazon Bio Discovery, an AI platform designed to accelerate antibody drug discovery by giving researchers direct access to a library of biological foundation models and enabling an agent-driven experiment-selection workflow. AWS said the platform includes tools to fine-tune model usage, evaluate candidate likelihoods, and route synthesis/testing requests to lab partners. The release includes workflow automation aimed at shrinking dry-lab-to-wet-lab cycles. AWS described a use case at Memorial Sloan Kettering in which the platform generated nearly 300,000 novel antibodies and directed the most promising 100,000 candidates into lab testing, delivered in weeks rather than traditional timelines. In the market context, the launch also drew attention to wet-lab CRO and manufacturing capacity, with analysts noting both potential demand uplift and competitive pricing pressure for protein characterization services.